ARTICLE | Clinical News
Eylea tops Lucentis, Avastin in some DME patients
February 19, 2015 1:56 AM UTC
A comparative effectiveness Eylea aflibercept from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) led to greater improvements in vision than did Lucentis ranibizumab or Avastin bevacizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), in patients with poor visual acuity at baseline.
The 660-patient NIH-sponsored study, published Wednesday in the New England Journal of Medicine, compared changes in visual acuity from baseline to one year with intravitreal injections of 2 mg Eylea, 1.25 mg Avastin and 0.3 mg Lucentis. ...